Summary
New research indicates that liquid biopsies can significantly enhance treatment for metastatic breast cancer patients, allowing tumors to remain controlled for over a year. By detecting mutations in cancer cells earlier than traditional imaging, these blood tests enable timely treatment adjustments, resulting in patients who switched to the experimental drug camizestrant experiencing tumor stability for 16 months, compared to nine months for those who did not switch. This approach offers a substantial improvement in managing the disease and maintaining patients’ quality of life.
